Cara Therapeutics tried to misdirect investors away from the failure of its osteoarthritis pain pill by burying negative results from a mid-stage clinical trial in the middle of a press release issued Thursday night. The ploy didn’t work. Cara shares plunged, with the stock trading down 30 percent to $17.99 this morning.

The lesson here: Read those clinical trial press releases slowly and carefully! Don’t get bamboozled.

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • Another lesson in how companies spin is when they set the bar so low, i.e., calling it a “safety study,” then go p-hacking/cherry picking for something positive to report. Worse still are fudged data.

  • Not necessarily negative. The results show they are on the right track but need to try a higher dose. 5 mg dose compared to other meds is still low. Foolish downgrade IMO

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy